Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring System. Alere has announced a voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR Monitoring ...
Alere has issued a voluntary correction to users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with the system (INRatio Monitor ...
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
Alere Inc will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 prothrombin time/international normalized ratio (PT/INR) monitoring system because of the potential for the ...
Alere has announced that its point-of-care INRatio and INRatio2 PT/INR Monitoring System, which was used to measure coagulation levels in the ROCKET AF trial, will be withdrawn from the market ...
Please provide your email address to receive an email when new articles are posted on . If I were a patient on long-term warfarin, I would want an international normalized ratio home monitor. It would ...
Real-world retrospective analysis of over 29,000 patients performing INR home monitoring for warfarin therapy shows excellent time in therapeutic range. Point-of-care, home international normalized ...
Continuing to address concerns about the device used to measure international normalized ratio (INR) values in ROCKET AF, trial leaders have released additional analyses of stored blood samples ...
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense® PT/INR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback